Bayer CEO advocates for 'speedboat' agility in large firms
Bayer CEO Bill Anderson is implementing a "speedboat" approach to increase agility at the 100,000-employee company. In a recent discussion, he outlined a focus on flattening hierarchy, empowering teams, and increasing the velocity of decision-making to turn around the legacy organization.
- This strategic shift, internally named "Dynamic Shared Ownership," aims to dismantle traditional hierarchies and empower self-managed teams. The goal is for 95% of decisions to be made by the people closest to the work, with innovation cycles shortening to 90 days. - Bill Anderson, who became CEO in June 2023, has a background in chemical engineering and previously served as CEO of Roche Pharmaceuticals and Genentech. His experience includes leading a major transformation program at Roche that resulted in significant revenue growth. - The restructuring is not just about speed but also a response to significant financial pressures, including the ongoing litigation Bayer inherited with its $63 billion acquisition of Monsanto in 2018. The company has already paid over $10 billion to settle claims that the Roundup herbicide causes cancer. - As part of the overhaul, Bayer has reduced its workforce by approximately 12,000 positions, with about half of those being management roles. This flattening of the organization is a core component of the "Dynamic Shared Ownership" model. - The "speedboat" analogy is part of a broader trend in large enterprises toward organizational agility, with frameworks like the Scaled Agile Framework (SAFe) and models like Scrum@Scale aiming to improve responsiveness and decision-making speed. - Early results from the new model have shown promise, with one consumer health team in Southeast Asia shortening internal processes by 60% and moving product launch dates forward by five to nine months. In the U.S. Pharmaceuticals division, 68 customer-focused "squads" have replaced four larger franchises. - Investor confidence has seen a notable recovery, with Bayer's stock price rebounding from lows in early 2025 to the mid-€40s by early 2026, driven by restructuring efforts and positive clinical trial news. However, analysts note that ongoing litigation and balance sheet risks remain key concerns. - The company is also pursuing a legal and legislative strategy to manage the Roundup litigation, including an appeal to the U.S. Supreme Court and lobbying for state-level legislation that would preempt failure-to-warn claims.
